Study to Assess the Safety, Tolerability and Pharmacokinetics of Brensocatib

Status: Ongoing

Details

INS1007-211 – A single-blind, placebo-controlled, parallel-group study to assess the safety, tolerability and pharmacokinetics of brensocatib administered once daily for 4 weeks in subjects with cystic fibrosis

Sponsor: Insmed

NCT04594369

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top